Chronic Lymphocytic Leukemia: Applying the Latest Data in Community Practice

Chronic Lymphocytic Leukemia: Applying the Latest Data in Community Practice (Virtual)

Wednesday, December 29, 2021
Webinar -- Simulcast12:00 PM ET
https://cmmglobal1.webex.com/cmmglobal1/onstage/g.php?MTID=e428d9e8ef6fd4bb4622558166d61ed51 Password:6610

Agenda

  • Overview of our evolving understanding of the genetics/pathogenesis of CLL
  • Case challenges in patients with treatment-naive CLL: treatment options for optimal outcomes
  • Case challenges in patients with relapsed/refractory CLL: current and novel treatment strategies
  • Intraclass and interclass comparison of current and emerging CLL therapies

Faculty

Faculty
Jeremy S. Abramson, MD, MMSc

Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts

Program Overview
This series of 1-hour, expert-led live workshops
present the latest best practices and clinically relevant investigational data for the optimal management of patients with chronic lymphocytic leukemia (CLL).

Goal Statement
The goal of this activity is to improve and accelerate the awareness, understanding, and integration of current and emerging best practices in the treatment of chronic lymphocytic leukemia.

Target Audience
This program is intended for physicians, nurses, pharmacists, and other healthcare professionals who treat and manage patients with chronic lymphocytic leukemia.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Plan individualized therapy to patients with newly diagnosed and relapsed/refractory CLL, based on available data, expert recommendations, and patient preferences to optimize outcomes and quality of life
  • Compare and contrast the known efficacy and toxicity profiles of available and investigational agents with the same target
  • Manage adverse events associated with the most common treatments for CLL to ensure treatment compliance as well as improved clinical outcomes and quality of life
  • Evaluate promising approved and investigational agents and combination regimens in CLL, including efficacy, unique toxicities, dosing, and other practical management considerations

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
UAN for live, in person: UAN: JA4008176-0000-21-140-L01-P
UAN for Virtual Meetings (Simulcasts, Webinars): JA4008176-0000-21-235-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.